Inpatient Closed-loop Glucose Control
Inpatient Closed-loop Glucose Control
The purpose of this study is to test an experimental medical device designed to automatically
 control blood sugar. This device was designed for use by patients with diabetes while they
 are in the hospital, and others who may develop high blood sugar as a result of their medical
 problems.
The goal of this first-in-man trial is to test the safety and efficacy of the automated,
 closed-loop control system in insulin sensitive subjects with type 1 diabetes, insulin
 sensitive subjects with type 2 diabetes (TTD > 1u/kg/day), and subjects with type 2 diabetes
 and substantial insulin resistance (<2 u/kg/day). The results of this study will help to
 design future studies, exploring the use of the closed-loop system for BG control in
 hospitalized patients, including those with diabetes or hyperglycemia of critical illness.
Inclusion Criteria

 Subjects with type 1 diabetes

 -  Age 21 to 75 with clinical type 1 diabetes for at least one year

 -  Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting
 insulins

 -  Total daily dose (TDD) of insulin that is < 1 u/kg

 Subjects with type 2 diabetes

 -  Age 21 to 75 with clinical type 2 diabetes for at least one year

 -  Diabetes managed using NPH as the basal insulin, which may be supplemented with
 regular or rapid-acting insulin

 -  Total daily dose (TDD) of insulin that is > 1 u/kg/day but < 2 u/kg/day or > 2
 u/kg/day

 Exclusion Criteria:

 -  Pregnancy

 -  Renal insufficiency

 -  Cancer

 -  Abnormal EKG suggestive of coronary artery disease or increased risk of malignant
 arrhythmia

 -  Acute illness or exacerbation of chronic illness at the time of the study procedure

 -  Use of non-insulin, injectable anti-diabetic medications or oral anti-diabetic
 medications other than metformin

 -  History of allergy or adverse reaction to aspirin, peptic ulcers or bleeding disorders

 -  Known history of coronary artery disease, TIA or stroke

 -  History of seizures

 -  Transaminitis

 -  Stage 2 hypertension at the time of screening